(redirected from Emtriva)
Also found in: Medical.
Related to Emtriva: Truvada, Viread


 (ĕm′trĭ-sĭt′ə-bēn′, -sī′tə-)
An antiviral drug, C8H10FN3O3S, that is a nucleoside reverse transcriptor inhibitor and is used in combination with other drugs to treat HIV infection or to reduce the risk of HIV infection.

[emtri- (probably Em(ory) University, where the drug was discovered + Tri(angle) Pharmaceuticals, company to which it was licensed) + -citabine, nucleoside analog antiviral and anticancer drug suff.; see zalcitabine.]


n emtricitabina
Mentioned in ?
References in periodicals archive ?
The company's HIV franchise includes Truvada, a combination of two of its other drugs, Viread and Emtriva.
s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta.
On August 2, 2012, Gilead Sciences, the world's largest maker of branded drugs to treat Human Immunodeficiency Virus (HIV), signed deals with Ranbaxy Laboratories, Strides Arcolab and Mylan to manufacture low-cost generic versions of its HIV drug Emtriva (emtricitabine) for sale in developing countries.
Gilead markets Emtricitabine under the brand name Emtriva, and a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate is available under the brand name Truvada.
Emtricitabine is marketed by Gilead under the brand name Emtriva, and a fixed-dose combination of Emtricitabine and Tenofovir Disoproxil Fumarate is made available under the brand name Truvada.
Preexposure prophylaxis (prEP) with Truvada, the entiretroviral pull that combines Viread (tenofovir) and Emtriva (emtricitabine), lowered the chance that HIV-negative gay men and transgender women would become infected in a large international trial.
Gilead Sciences and Bristol-Myers Squibb announce a collaboration to combine Sustiva, Emtriva, and Viread into a once-daily, one-pill regimen.
Atripla, the first one-pill product to treat HIV/AIDS, combines the active ingredients of Sustiva, Emtriva and Viread.
Sustiva is a nonnucleoside reverse transcriptase inhibitor and Emtriva and Viread are nucleoside reverse transcriptase inhibitors.
The two drugs are Viread (tenofovir) and FTC, or Emtriva (emtricitabine).
Gilead press release, August 26, 2004: Gilead announces preliminary 24-week data from study 934 comparing Viread and Emtriva to Combivir both in combination with efavirenz in patients with HIV.